“Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4”: Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping-Reference-Cited by-同舟云学术

“Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4”: Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping

Published:2019-12-13 Issue:2 Volume:33 Page:281-282
ISSN:0893-228X
Container-title:Chemical Research in Toxicology
language:en
Short-container-title:Chem. Res. Toxicol.

Author:

Veeravalli Vijayabhaskar¹²,Dash Ranjeet P.¹²³^ORCID

Affiliation:

1. Johns Hopkins Drug Discovery, Johns Hopkins University, 855 North Wolfe Street, Baltimore, Maryland 21205, United States

2. Department of Neurology, Johns Hopkins University, 855 North Wolfe Street, Baltimore, Maryland 21205, United States

3. ADME-DMPK, Charles River Laboratories, Ashland, Ohio 44805, United States

Publisher

American Chemical Society (ACS)

Subject

Toxicology,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.chemrestox.9b00455

Reference13 articles.

1. Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

2. An evaluation of tofacitinib for the treatment of psoriatic arthritis

3. Pharmacodynamic Analysis of Tofacitinib and Basiliximab in Kidney Allograft Recipients

4. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers

5. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to Letter to Editor from Veeravalli and Dash on “Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4: Revisiting the Significance of the Epoxide Intermediate and Glutathione Trapping”;Chemical Research in Toxicology;2020-05-29

2. Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment;Drug Safety;2020-05-04